Extract Technology Acquired by Dec Group, Expanding Presence in Advanced Therapies
The acquisition is reported to expand the companies’ presence in the ATMP market.
Extract Technology, manufacturer of GMP cell processing work environments, was recently acquired by Dec Group, Dietrich Engineering Consultants, headquartered in Lausanne, Switzerland. The acquisition brings Dec Group ISO-9001 and NQA-1 manufacturing sites in two additional countries and broadens their presence in biopharmaceutical and radiopharmaceutical markets.
Dec Group recognizes the ATMP market and Extract’s cell therapy product offerings serve a critical and revolutionary industry. Many regulatory and industry organizations share this enthusiasm. A recent article from the European Medicines Agency states that ATMPs ‘offer ground-breaking new opportunities for the treatment of disease and injury.’
The ATMP space is developing rapidly having an incredible impact on patient treatment options. Over a decade ago Extract Technology provided cell therapy isolators with integrated lab equipment including incubators. Shortly after, their R&D efforts led to the development of patented aseptic docking technology allowing scalable modular incubators to be docked on standardised cell processing isolators. Cross contamination risks can be mitigated by the use of such isolators over biosafety cabinets. Modular cell therapy isolators offer an ISO 5 grade A work environment that can be placed in any grade of new or existing cleanroom.
As Matt Pridden, Global Standard Products Development Manager at Extract Technology explained:
“More and more we’re seeing this industry choose modular solutions like this because of the cost savings. Heating and cooling, space, mitigating contamination risks and the cost of it too. The labs we work in are large and expensive and this provides an efficient and ergonomic solution for cell processing workflows.”
Extract Technology has over 40 years in aseptic and containment systems for pharmaceutical, biopharmaceutical, nuclear containment and radiopharmaceutical applications. Specialising in isolators with process integrations including for use in clinical development, cell and gene therapy processing, sterility testing and liquid and powder filling, as well as manufacturing Mobile Cleanrooms, LAF Carts, RABs and Downflow Booths. Extract Technology’s pharmaceutical products as well as the Walker Barrier Systems brand of Nuclear Containment Gloveboxes, are reported to ‘proceed in leading in their key industrial markets with strength under new owners, DEC Group’.
Dec (Dietrich Engineering Consultants) Group is a leading global provider of contained powder handling systems and is recognized as a world-leading expert in process containment technologies. It has been supplying the pharmaceutical, chemical, food and cosmetic industries for more than 30 years. Dec offers innovative approaches across the range of powder handling and process containment applications, including transfer, micronizing, filling/emptying, sampling, blending, dosing, aseptic solutions, milling, isolators and advanced cleaning (CIP/SIP) features.
For more information, contact Extract Technology here.
Lead image: This cell therapy isolator is primarily used to produce allogeneic mesenchymal stromal/stem cells. It is installed at the Finnish Red Cross Advanced Cell Therapy Center (ACTC) at Helsinki University Hospital, Finland. Posted with permission of Extract Technology.